{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-053588","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2025-06-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.324027+00:00","generated_at":"2026-05-19T11:18:31.297286+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Incannex cancels all Series A Warrants, eliminating 347.2M shares of potential dilution","bullets":["Cancelled remaining 172M Series A Warrants for $12.2M via ATM facility; combined with earlier tranche removes 347.2M shares.","CEO Joel Latham says cancellation eliminates significant dilution ahead of Phase 2 RePOSA topline data for IHL-42X in July 2025.","IHL-42X is a potential first-in-class oral therapy for obstructive sleep apnea, a condition with no FDA-approved drug."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-053588","json":"https://secwatch.observer/filing/0001213900-25-053588.json","markdown":"https://secwatch.observer/filing/0001213900-25-053588.md","text":"https://secwatch.observer/filing/0001213900-25-053588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025053588/0001213900-25-053588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390025053588/ea0245396-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T11:18:31.297286+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}